With Pfiz­er in hot pur­suit, J&J los­es a crit­i­cal patent fight as it scram­bles for a new prostate can­cer drug OK

J&J’s block­buster prostate can­cer drug Zyti­ga has just been pushed per­ilous­ly close to the edge of the patent cliff. And with its fran­chise tee­ter­ing on the brink, the phar­ma gi­ant is left scram­bling for an OK of a suc­ces­sor ther­a­py that may soon find it­self go­ing head-to-head with Pfiz­er’s Xtan­di.

The US Patent Tri­al and Ap­peal Board ruled that a patent cov­er­ing the ad­min­is­tra­tion of Zyti­ga was im­prop­er­ly al­lowed as the ap­proach was ob­vi­ous, Reuters re­port­ed Wednes­day night. The com­pa­ny im­me­di­ate­ly put out a state­ment that it was re­view­ing its op­tions for a re­hear­ing on the in­ter partes re­views de­ci­sion, or a shift to a fed­er­al ap­peals court.

You can be sure that J&J $JNJ won’t roll over eas­i­ly on this one.

The ac­tion was brought by Ar­gen­tum Phar­ma­ceu­ti­cals, a gener­ics out­fit which has been strip­ping away the patents that guard a fran­chise worth more than $2 bil­lion a year.

If J&J los­es this bat­tle, it still has a late-stage drug in front of the FDA — apa­lu­tamide, or ARN-509 — it’s hop­ing can pro­tect the big rev­enue stream it gets from Zyti­ga (abi­raterone), an oral drug that has helped rev­o­lu­tion­ize prostate can­cer treat­ment over the last 5 years.

J&J won a pri­or­i­ty re­view of apa­lu­tamide for non­metasta­t­ic cas­tra­tion re­sis­tant prostate can­cer, an ear­ly des­ig­na­tion. And it’s field­ing Phase III da­ta that is slat­ed to be re­vealed at the AS­CO Gen­i­touri­nary Can­cers Sym­po­sium on Feb­ru­ary 8. The ac­cel­er­at­ed PDU­FA date is in April.

But Pfiz­er $PFE is al­so in the hunt to gain an ap­proval for Xtan­di — a drug part­nered with Astel­las and picked up in the $14 bil­lion Medi­va­tion buy­out — in the same in­di­ca­tion. Af­ter a change­up in its tri­al de­sign that cut the chase for piv­otal da­ta by two years, the phar­ma gi­ant head­lined topline da­ta last Sep­tem­ber that showed that Xtan­di com­bined with an­dro­gen de­pri­va­tion ther­a­py beat ADT alone on metas­ta­sis-free sur­vival rates for non­metasta­t­ic prostate can­cer. And now it’s look­ing for a la­bel ex­pan­sion.

The fi­nal num­bers on both stud­ies will be care­ful­ly watched as the two gi­ants hus­tle for an ap­proval. Bil­lions rest on the out­come of that race.

J&J’s state­ment this evening notes:

“We are dis­ap­point­ed in and strong­ly dis­agree with the U.S. Patent and Trade­mark Of­fice’s (USP­TO) de­ci­sions re­lat­ing to Zyti­ga as part of the In­ter Partes Re­views. We are eval­u­at­ing our op­tions with re­spect to a re­quest for re­hear­ing and/or ap­peal to the Court of Ap­peals for the Fed­er­al Cir­cuit. We be­lieve the ‘438 patent is valid and will con­tin­ue to vig­or­ous­ly de­fend it.”

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma. I’ve had a couple of faceplants earlier this year, watching some of the biotechs on my short list choose a quick leap onto Nasdaq or into the arms of a buyer.

Vividion, you would have been a great pick for the Endpoints 11. I’m sorry I missed you.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Dave Lennon, former president of Novartis Gene Therapies

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last couple of days it’s become clear that the gene therapy division at Novartis has quietly undergone a major reorganization. We learned on Monday that Dave Lennon, who had pursued a high-profile role as president of the unit with 1,500 people, had left the pharma giant to take over as CEO of a startup.

Like a lot of the majors, Novartis is an open highway for head hunters, or anyone looking to staff a startup. So that was news but not completely unexpected.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

FDA+ roundup: Bs­U­FA III ready for show­time, court tells FDA to re-work com­pound­ing plan, new guid­ance up­dates and more

The FDA has now spelled out what exactly will be included in the third iteration of Biosimilar User Fee Act (BsUFA) from 2023 through 2027, which similarly to the prescription drug deal, sets fees that industry has to pay for submitting applications, in exchange for firm timelines that the agency must meet.

This latest deal includes several sweeteners for the biosimilar industry, which has yet to make great strides in the US market, with shorter review timelines for safety labeling updates and updates to add or remove an indication that does not contain efficacy data.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jean Bennett (Brent N. Clarke/Invision/AP Images)

Lux­tur­na in­ven­tor Jean Ben­nett starts a new gene ther­a­py com­pa­ny to tack­le rare dis­eases left be­hind by phar­ma, VCs

A few years ago Jean Bennett found herself in a surprising place for a woman who invented the first gene therapy ever approved in the United States: No one, it seemed, wanted her work.

Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab. But although the results in animals looked promising, pharma companies and investors kept turning down the pedigreed ophthalmology professor.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,900+ biopharma pros reading Endpoints daily — and it's free.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Maureen Hillenmeyer, Hexagon Bio CEO

Hexa­gon Bio rais­es $61M to con­tin­ue ef­forts to turn fun­gi in­to drugs

A year after raising a $47 million launch round, the fungi-loving drug hunters at Hexagon Bio have more than doubled their coffers.

Hexagon announced today that it raised another $61 million for its efforts to design cancer and infectious disease drugs based on insights mined from the DNA in millions of species of fungi. The new financing brings Hexagon’s committed funding to over $108 million.